The mechanisms underlying Chinese medicines to treat inflammation in diabetic kidney disease
- 4 June 2024
- journal article
- research article
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 333, 118424
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (32141005, 82070741, 82270758, 82200797)
This publication has 164 references indexed in Scilit:
- Qi‐dan‐dihuang decoction ameliorates renal fibrosis in diabetic rats via p38MAPK/AKT/mTOR signaling pathwayEnvironmental Toxicology, 2024
- Astragaloside IV attenuates high glucose‐induced NF‐κB‐mediated inflammation through activation of PI3K/AKT‐ERK‐dependent Nrf2/ARE signaling pathway in glomerular mesangial cellsPhytotherapy Research, 2023
- Sclareol ameliorates hyperglycemia‐induced renal injury through inhibiting the MAPK / NF‐κB signaling pathwayPhytotherapy Research, 2022
- Celastrol attenuates renal injury in diabetic rats via MAPK/NF‐κB pathwayPhytotherapy Research, 2019
- A branched arabinoglucan from Angelica sinensis ameliorates diabetic renal damage in ratsPhytotherapy Research, 2019
- Nobiletin suppresses high‐glucose–induced inflammation and ECM accumulation in human mesangial cells through STAT3/NF‐κB pathwayJournal of Cellular Biochemistry, 2018
- JAK inhibition in the treatment of diabetic kidney diseaseDiabetologia, 2016
- Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db miceDiabetologia, 2009
- Role of MKK3–p38 MAPK signalling in the development of type 2 diabetes and renal injury in obese db/db miceDiabetologia, 2008
- Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathyDiabetologia, 2004